Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia

被引:27
|
作者
Alves, Brunna E. [1 ]
Montalvao, Silmara A. L. [1 ]
Aranha, Franciso J. P. [1 ]
Siegl, Tania F. G. [1 ]
Souza, Carmino A. [2 ]
Lorand-Metze, Irene [2 ]
Annichino-Bizzacchi, Joyce M. [2 ]
De Paula, Erich V. [1 ]
机构
[1] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil
[2] Univ Estadual Campinas, Fac Med Sci, Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
EXCESS CIRCULATING ANGIOPOIETIN-2; MULTINATIONAL-ASSOCIATION; SUPPORTIVE-CARE; ORGAN FAILURE; SEVERE SEPSIS; RISK-INDEX; DYSFUNCTION; GUIDELINES; MORTALITY;
D O I
10.1186/1471-2334-10-143
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Febrile neutropenia carries a high risk of sepsis complications, and the identification of biomarkers capable to identify high risk patients is a great challenge. Angiopoietins (Ang -) are cytokines involved in the control microvascular permeability. It is accepted that Ang-1 expression maintains endothelial barrier integrity, and that Ang-2 acts as an antagonizing cytokine with barrier-disrupting functions in inflammatory situations. Ang-2 levels have been recently correlated with sepsis mortality in intensive care units. Methods: We prospectively evaluated concentrations of Ang-1 and Ang-2 at different time-points during febrile neutropenia, and explored the diagnostic accuracy of these mediators as potential predictors of poor outcome in this clinical setting before the development of sepsis complications. Results: Patients that evolved with septic shock (n = 10) presented higher levels of Ang-2 measured 48 hours after fever onset, and of the Ang-2/Ang-1 ratio at the time of fever onset compared to patients with non-complicated sepsis (n = 31). These levels correlated with sepsis severity scores. Conclusions: Our data suggest that imbalances in the concentrations of Ang-1 and Ang-2 are independent and early markers of the risk of developing septic shock and of sepsis mortality in febrile neutropenia, and larger studies are warranted to validate their clinical usefulness. Therapeutic strategies that manipulate this Ang-2/Ang-1 imbalance can potentially offer new and promising treatments for sepsis in febrile neutropenia.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score
    Aagaard, Theis
    Roen, Ashley
    Reekie, Joanne
    Daugaard, Gedske
    Brown, Peter de Nully
    Specht, Lena
    Sengelov, Henrik
    Mocroft, Amanda
    Lundgren, Jens
    Helleberg, Marie
    JNCI CANCER SPECTRUM, 2018, 2 (04)
  • [32] Clinical Usefulness of Serum Lactate Level as an Effective Predictor of Septic Shock within 48 Hours in Hemodynamically Stable Children With Febrile Neutropenia
    Rujkijyanont, P.
    Prasertsin, W.
    Suwanpakdee, D.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S175 - S175
  • [34] Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia
    Kim, Youn-Jung
    Jung, Sung Min
    Kang, Jihoon
    Ryoo, Seung Mok
    Sohn, Chang Hwan
    Seo, Dong-Woo
    Lim, Kyoung Soo
    Huh, Jin Won
    Kim, Sung-Han
    Kim, Won Young
    INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (03) : 433 - 440
  • [35] Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia
    Youn-Jung Kim
    Sung Min Jung
    Jihoon Kang
    Seung Mok Ryoo
    Chang Hwan Sohn
    Dong-Woo Seo
    Kyoung Soo Lim
    Jin Won Huh
    Sung-Han Kim
    Won Young Kim
    Internal and Emergency Medicine, 2019, 14 : 433 - 440
  • [36] Prospective evaluation of early discharge of patients with chemotherapy-induced febrile neutropenia and hematological malignancies.
    Wasi, P
    Henderson, N
    Hammond, C
    Walker, IR
    BLOOD, 2000, 96 (11) : 322A - 322A
  • [37] Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy
    Frem, Jim Abi
    Khazzeka, Alicia
    Allaw, Fatima
    Doueiry, Caren
    Ghoussaini, Racha
    Mohamad, Rayan
    Kanafani, Zeina A.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [38] Electrolyte imbalances in patients admitted with chemotherapy-induced febrile neutropenia: Patterns and impact on outcomes, a single-centre study from Pakistan
    Shaikh, A. J.
    Masood, N.
    Adil, S. N.
    Bawany, S. A.
    Khan, A. A.
    Kumar, S.
    Lal, A.
    Zaidi, A.
    Niamutullah, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Time to first febrile neutropenia among early stage breast cancer patients receiving adjuvant chemotherapy.
    Scott, SD
    Chrischilles, EA
    Link, BK
    Delgado, DJ
    Fridman, M
    Lyman, GH
    PHARMACOTHERAPY, 2003, 23 (03): : 406 - 406
  • [40] LOW RATE OF INFECTIOUS RELATED ADVERSE EVENTS, SEPTIC SHOCK AND MORTALITY IN ACUTE LEUKEMIA PATIENTS WITH POST-CHEMOTHERAPY SEVERE NEUTROPENIA, IN ABSENCE OF FLUORQUINOLONE PROPHYLAXIS
    Zappone, E.
    Bocchia, M.
    Betti, C.
    Defina, M.
    Ciofini, S.
    Brambilla, C. Zuanelli
    Mecacci, B.
    Sammartano, V.
    De Martino, F.
    HAEMATOLOGICA, 2019, 104 : 151 - 151